Literature DB >> 12919132

Association of autism severity with a monoamine oxidase A functional polymorphism.

I L Cohen1, X Liu, C Schutz, B N White, E C Jenkins, W T Brown, J J A Holden.   

Abstract

A functional polymorphism (the upstream variable-number tandem repeat region, or uVNTR) in the monoamine oxidase A (MAOA) promoter region has been reported to be associated with behavioral abnormalities as well as increased serotonergic responsivity. We examined the relation between MAOA-uVNTR alleles and the phenotypic expression of autism in 41 males younger than 12.6 years of age. Children with the low-activity MAOA allele had both lower intelligence quotients (IQ) and more severe autistic behavior than children with the high-activity allele. In follow-up testing of 34 of the males at the 1-year time-point, those with the low-activity allele showed a worsening in IQ but no change in the severity of their autistic behavior. We conclude that functional MAOA-uVNTR alleles may act as a genetic modifier of the severity of autism in males.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919132     DOI: 10.1034/j.1399-0004.2003.00115.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  53 in total

1.  Autism Spectrum Disorder Decision Tree Subgroups Predict Adaptive Behavior and Autism Severity Trajectories in Children with ASD.

Authors:  Ira L Cohen; Michael J Flory
Journal:  J Autism Dev Disord       Date:  2019-04

2.  Association of MAOA, 5-HTT, and NET promoter polymorphisms with gene expression and protein activity in human placentas.

Authors:  Huiping Zhang; Graeme N Smith; Xudong Liu; Jeanette J A Holden
Journal:  Physiol Genomics       Date:  2010-03-23       Impact factor: 3.107

3.  2p15-p16.1 microdeletion syndrome: molecular characterization and association of the OTX1 and XPO1 genes with autism spectrum disorders.

Authors:  Xudong Liu; Patrick Malenfant; Chelsea Reesor; Alana Lee; Melissa L Hudson; Chansonette Harvard; Ying Qiao; Antonio M Persico; Ira L Cohen; Albert E Chudley; Cynthia Forster-Gibson; Evica Rajcan-Separovic; M E Suzanne Lewis; Jeanette J A Holden
Journal:  Eur J Hum Genet       Date:  2011-07-13       Impact factor: 4.246

4.  Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine.

Authors:  Mari S Golub; Casey E Hogrefe; Alicia M Bulleri
Journal:  Neuropharmacology       Date:  2016-02-22       Impact factor: 5.250

5.  Association of dopamine transporter and monoamine oxidase molecular polymorphisms with sudden infant death syndrome and stillbirth: new insights into the serotonin hypothesis.

Authors:  Laura Filonzi; Cinzia Magnani; Anna Maria Lavezzi; Guido Rindi; Stefano Parmigiani; Giulio Bevilacqua; Luigi Matturri; Francesco Nonnis Marzano
Journal:  Neurogenetics       Date:  2008-09-23       Impact factor: 2.660

Review 6.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Association of a monoamine oxidase-a gene promoter polymorphism with ADHD and anxiety in boys with autism spectrum disorder.

Authors:  Jasmin Roohi; Carla J DeVincent; Eli Hatchwell; Kenneth D Gadow
Journal:  J Autism Dev Disord       Date:  2008-06-20

8.  MAOA-uVNTR and early physical discipline interact to influence delinquent behavior.

Authors:  Alexis C Edwards; Kenneth A Dodge; Shawn J Latendresse; Jennifer E Lansford; John E Bates; Gregory S Pettit; John P Budde; Alison M Goate; Danielle M Dick
Journal:  J Child Psychol Psychiatry       Date:  2009-11-27       Impact factor: 8.982

Review 9.  Diagnostic and Severity-Tracking Biomarkers for Autism Spectrum Disorder.

Authors:  Geir Bjørklund; Nagwa A Meguid; Afaf El-Ansary; Mona A El-Bana; Maryam Dadar; Jan Aaseth; Maha Hemimi; Joško Osredkar; Salvatore Chirumbolo
Journal:  J Mol Neurosci       Date:  2018-10-24       Impact factor: 3.444

10.  The serotonergic system: its role in pathogenesis and early developmental treatment of autism.

Authors:  D I Zafeiriou; A Ververi; E Vargiami
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.